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Abstract
Donor-specific (d-sp) interferon gamma enzyme-linked immunosorbent spot (d-sp ELISPOT)
and Panel of reactive T-cell (PRT) ELISPOT assays have been developed to detect alloreactive
memory T (Tmem) cells in order to estimate the risk of acute rejection after kidney transplanta-
tion. Adding IL15 to the PRT assay (PRT+IL15) may uncover the presence of pathogenic allor-
eactive CD28-Tmem. Face-to-face comparisons of these assays have not been done yet. We
performed pre-transplant d-sp ELISPOT and PRT assays (±IL15, against six B-cell lines) in 168
consecutive kidney transplant recipients and evaluated the multivariable-adjusted associations
with biopsy-proven acute rejection (BPAR), de novo donor-specific antibodies (DSA), and
eGFR decline over a 48-month follow-up period. D-sp ELISPOTwas positive in 81 (48%) sub-
jects, while 71 (42%) and 81 (48%) subjects displayed positive PRT and PRT+IL15, respec-
tively. Their median [interquartile range] numerical test result was 23 [6–65], 18 [8–37], and 26
[10–45] spots/3x105 PBMCs, respectively. The number of PRT spots were weakly correlated
with those of d-sp ELISPOT, but highly correlated with PRT+IL15 (rho = 0.96, P<0.001). d-sp
ELISPOT, but not PRT (±IL15) was independently associated with BPAR (adjusted Odds Ratio
of BPAR associated with d-sp ELISPOT positivity: 4.20 [95%CI: 1.06 to 21.73; P = 0.041]).
Unlike d-sp ELISPOT, median PRT and PRT+IL15 were independently associated with higher
Δ3-48month eGFR decline post-transplantation (for both assays, about -3mL/min/1.73m2 per
one standard deviation unit increase in the spot number). Pre-transplant T-cell immune-monitor-
ing using d-sp ELISPOT and PRT assays identifies kidney transplant candidates at high risk of
BPAR and worse kidney allograft progression.
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Introduction
Currently, immunosuppressive therapy in kidney transplant patients is largely chosen on the basis
of center-specific protocols and is empirically guided by nonspecific clinical parameters including
serum creatinine, circulating drug levels, and kidney biopsies [1–4]. As a result, there are some
patients receiving too little immunosuppression and others unnecessarily exposed to the toxicities
of inadequately high doses of immunosuppressive drugs [5,6]. Therefore, tools to monitor alloim-
mune response in a non-invasive and specific manner are urgently needed to tailor immunosup-
pression according to the individual-patient immunological risk [7–11].
The notion that alloreactive memory T cells (Tmem) are crucial mediators of allograft rejec-
tion led to the development of the cytokine enzyme-linked immunospot (ELISPOT) assay
which is able to quantify circulating alloreactive Tmem at the single cell level [12,13]. Initial
studies have shown that pre-transplantation d-sp ELISPOT correlates with biopsy-proven
acute rejection (BPAR) after kidney transplantation [14,15] and could be used to tailor immu-
nosuppression [16–19]. In 2015, a large prospective-cohort study of 176 kidney transplant
patients surprisingly failed to observe a relationship between positive pre-transplant d-sp ELI-
SPOT and BPAR, but detected a relationship between and lower one-year graft function in
patients not receiving thymoglobulin induction. This relationship was absent in patients
induced with thymoglobulin, suggesting that thymoglobulin diminishes the risk of graft injury
in patients with a positive d-sp ELISPOT before transplant [20].
A major drawback of the d-sp ELISPOT assay is that it requires donor cells and over 24
hours to be performed, making it impractical in cadaveric kidney recipients [21]. To address
this issue, a T-cell reactivity index, or panel of reactive T-cells (PRT) has been proposed utiliz-
ing the ELISPOT responses to common HLA antigens from a pool of donors reflective of gen-
eral organ donor pool. Similar to the panel-reactive antibody test for identifying individuals
with elevated levels of anti-HLA antibodies, the PRT may identify patients at risk for post-
transplantation cellular-mediated graft injury [21]. In a small study of 30 kidney transplant
patients, six of the seven (86%) patients with acute rejection were PRT-positive whereas only
one had low PRT before transplantation [22]. Other small, retrospective studies reported an
association between positive pre-transplant PRT and increased risk of acute rejection [23].
However, the utility of PRT in predicting graft outcomes has not yet been investigated in larger
cohorts of kidney transplant patients. Additionally, a comparison of the performance of the d-
sp ELISPOT assay and the PRT assay has not been evaluated yet.
Emerging data identified circulating CD28- T cells as crucial population for both allograft
tolerance and rejection [24–26]. These cells do not proliferate nor produce IFN-γ in regular
mixed lymphocyte reaction assays, but can be unraveled by adding IL-15 to the assay [27,28].
In vivo, IL-15 is produced by renal epithelial cells and promotes the recruitment and activation
of alloreactive CD28- T cells. Therefore, quantifying these cells pre-transplant by adding IL15
to standard PRT may be important in stratifying the risk of BPAR [27].
In this large retrospective-cohort study, we performed pre-transplant d-sp ELISPOT and
PRT (±IL15) in 168 consecutive kidney transplant recipients and evaluated their independent
relationship with the development of BPAR and other transplant outcomes including de novo
DSA, graft function and graft failure.
Materials andmethods
Patients and interventions
This retrospective-cohort study included all consecutive adult patients (18 years) who
received a kidney transplant from living or deceased donors at Bellvitge University Hospital,
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Barcelona, Spain, from 2011 to 2013 who had donor and recipient blood or spleen samples
available. Exclusion criteria included multiple organ transplant recipients, ABO incompatible
transplants, and positive complement-dependent cytotoxicity cross-match. The study was
approved by Institutional Review Board (IRB) (HUB PR228/13) of the Bellvitge University
Hospital and all eligible patients provided written informed consent for study participation.
None of the transplant donors were from a vulnerable population and all donors or next of kin
provided written informed consent that was freely given.
Estimated GFR (CKD-EPI) [29] and 24h-proteinuria were assessed at 3, 6, 12, 24, 36 and 48
months post-transplantation. All patients underwent graft biopsy in the case of clinical dys-
function. All biopsy samples were scored following the international Banff 2013 classification
criteria [30].
Delayed graft function (DGF) was defined as the need for dialysis during the first week after
transplant. Patients were followed-up until October 31st 2016 or graft failure (dialysis or death
with a functioning graft).
Immunosuppressive therapy consisted of induction with thymoglobulin (total dose: 4.5
mg/kg over 5 days) or basiliximab (20 mg on days 0 and 4). Maintenance immunosuppressive
treatment consisted of tacrolimus or cyclosporine, mycophenolate mofetil (MMF) and ste-
roids. Steroid withdrawal was undertaken at 3 months after transplant based on clinical criteria
in those patients with stable renal function and no previous BPAR episodes.
Donor-specific ELISPOT and PRT results were unavailable to the clinicians in charge of the
patients and therefore had no influence on the choice of immunosuppression and clinical
management of the transplant patients.
Donor-specific ELISPOT assay
Donor-specific ELISPOT assay was performed as previously described [16,31]. In brief, recipi-
ent peripheral blood mononuclear cells (PBMCs) (harvested on the day of transplant before
the administration of any immunosuppressive drug) were isolated by Ficoll gradient centrifu-
gation. Donor cells were obtained from donor spleens or PBMCs in deceased and living
donors, respectively. Donor and recipient cells were frozen in liquid nitrogen and defrosted on
the day of the ELISPOT or PRT assays. Deceased-donor splenocytes were CD2-depleted and
living-donor PBMCs were CD3-depleted. Recipient PBMCs (3x105 cells/well) were tested in
triplicate wells with respective donor cells (3x105 cells/well) in 96-well plates. Anti-third party
cells (full mismatch A, B and DR splenocytes) were also used as stimulators and evaluated in
triplicate wells. PBMCs plus medium alone served as a negative control and phytohemaggluti-
nin (PHA) stimulation was used as a positive control.
PRT assay
The lowest number of stimulator B cells and PBMCs able to provide results highly correlated
(S1 Fig; R2: 0.94; P<0.0001) with the ones obtained with standard technique [22,23] was
100.000 responder PBMCs against 60.000 in vitro expanded (not EBV transformed) allogeneic
B-cell stimulators. Therefore, we used these numbers of cells for all our experiments in a
384-well plate. Each responder was tested in duplicate against a panel of six previously frozen
B-cell stimulators (HLA typing provided in S1 Table) with or without the addition of IL15 (1
ng/mL, Biolegend). PBMCs plus medium alone or IL15 served as negative controls for PRT
and PRT-IL15, while PHAserved as positive controls.
We optimized PRT IL-15 assay by testing increasing concentrations of IL-15: 0.5, 1, 3, 5, 7,
10, 50, and 100 ng/mL. We found that 1 ng/mL of IL-15 was able to increase the number of
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recipient PBMCs reactivity against B-cells without significantly increasing the number of spot
in PBMCs not exposed to B cells and only to medium alone (data not shown).
B cell lines were obtained from Dr. Heeger (Icahn School of Medicine at Mount Sinai, New
York, US) [22]. Briefly, B cells were isolated and expanded from a panel of from 6 distinct
donor spleen cells or PBMC. B cells have been expanded in vitro by culturing them with cyto-
kines (IL-2 and IL-4) and CD40L transfected fibroblasts. In order to confirm that B cell lines
represented donor HLA repertoires in our cohort of patients, the expression of common HLA
A, B and DR alleles was studied in this cohort regarding B cell lines HLA typing. As shown in
S2 Fig, B cell panel HLA alleles represented 61.95%, 59.27% and 78.86% of expression over all
HLA A, HLA B and HLA DR alleles expressed in our donor cohort, respectively. Importantly,
besides covering a great proportion of our donor HLA repertoire, the HLA type of the B cell
lines represented the most frequent alleles of our donor cohort population.
Spot quantification
The spots for d-sp ELISPOT were quantified using the AID1 ELISPOT reader 4th generation
(Autoimmun Diagnostika, Strassberg, Germany) and for PRT using the ImmunospotS4 Core
Analyzer (CTL, Shaker Heights, OH, USA) by two independent researchers and averaged. We
determined mean numbers of d-sp ELISPOTs per 3x105 responder PBMCs from triplicate
wells. Spots detected in control wells without stimulators were subtracted from the total num-
ber of spots.
To determine d-sp ELISPOT positivity, we used the previously published threshold of25
IFN-γ spots/3x105 PBMC14. This choice was supported by an analysis aimed at identifying the
best cut-off point (data not shown), that compared the Akaike information criterion between
regression models for BPAR which differed for the selected d-sp ELISPOT positivity cutpoint.
We analyzed PRT and PRT +IL15 as continuous variables represented by the median num-
ber of spots/3x105 PBMCs against the 6 B-cell lines. We defined PRT positivity against a B cell
line as40 spots/3x105 PBMCs, and50 spots/3x105 for PRT +IL15 (cut-offs that were the
approximate lower bound of the upper quintile of median PRT and PRT+IL15, respectively).
Also, patients were classified as belonging to the category of “positive” PRT when PRT ELI-
SPOTs were positive against at least one of the six B-cell lines, or to the “negative” PRT cate-
gory when PRT ELISPOTs were negative against all the six B-cell lines.
Circulating anti-HLA antibodies
Screening for circulating anti-HLA class I and II alloantibodies was done in all patients prior
to transplantation and in a subset of 117 patients (69%) at least once after transplantation
according to serum availability, using single-antigen flow bead assays on a Luminex platform
(Lifecodes, a division of Immucor, Stamford, CT). All beads showing a normalized mean fluo-
rescence intensity of>1500 MFI were considered positive if (mean fluorescence intensity/
[mean fluorescence intensity lowest bead])> 5.
Statistical analyses
All analyses were performed using the statistical package Stata Statistical Software package,
Release 15.0. (StataCorp, College Station, TX). A two-tailed p-value less than 0.05 was regarded
as statistically significant.
Estimates were expressed as differences between positive vs. negative d-sp ELISPOT, differ-
ences between positive vs negative PRT (and PRT+IL15), or as changes per one unit standard
deviation of the continuous variables of d-sp ELISPOTs, median PRT, and median PRT+IL15,
which were approximately 50, 25, and 30 IFN-γ spots/3x105 PBMCs for d-sp ELISPOT, PRT
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and PRT+IL15, respectively. Linearity of the continuous variables was tested using fractional
polynomials.
We estimated the association between baseline recipients’ characteristics and the mean
number of IFN-γ spots of d-sp ELISPOT, PRT and PRT+IL15 using gamma regression via
generalized linear models with robust standard errors, due to the non-normal distribution
with long right tails of the dependent variables.
We used the Kaplan–Meier method to estimate the crude probability of uncensored and
death-censored graft survival and Cox regression models to examine the multivariable-
adjusted relationship between d-sp ELISPOT, PRT, PRT+IL15 and graft failure. Logistic
regression models, with the statistical inference based on the likelihood ratio test, were used to
estimate multivariable-adjusted odds ratios of BPAR and de novo DSA associated with d-sp
ELISPOT and PRT (and PRT+IL15). Because of the virtual absence of BPAR-outcomes in
patients receiving thymoglobulin induction, all the analyses were repeated in the subset of
patients not receiving thymoglobulin induction.
For the analysis of 48-months longitudinal changes of eGFR and of Log(proteinuria) from
baseline, set at 3 months post-transplantation, we fitted repeated measures linear mixed mod-
els using restricted maximum likelihood to take into account of the presence of unbalanced
data (i.e. not all patient had the eGFR measured at each time point). All the reported hypothe-
sis tests for the fixed effects were based on a small-sample adjustment [32]. We checked nor-
mality distribution assumption by inspecting histograms and standardized normal probability
plot of residuals, and homogeneity of variance assumption by inspecting residuals-vs-fitted
plots. We verified model fitting by inspecting observed-vs-fitted-values plots, and observed-vs-
fitted-individual-eGFR-trajectories plots.
All multivariable-adjusted regression models included, whenever applicable, the following
characteristics: baseline eGFR, baseline 24h-proteinuria, recipient and donor age, living (vs
deceased) donor, cold ischemia time, thymoglobulin induction (indicator variable 1 if yes, 0 if
otherwise), re-transplantation, pre-transplant HLA antibodies (indicator variable 1 if cPRA
>5%, 0 if otherwise), HLA A/B and HLA DRmismatch, glomerulonephritis as primary renal
disease (indicator variable 1 if yes, 0 if otherwise), dialysis vintage, and prednisone withdrawal.
We used themargins Stata command to calculate crude and adjusted means, crude and




The study included 168 patients who were followed-up for a median (interquartile range)
period of 45 (37–61) months. Patients were mainly Caucasian and recipients of cadaveric
donors (Table 1). Only a minority of recipients were at increased immunological risk either
because of re-transplantation (13%) or because of pre-formed HLA circulating antibodies
(12%). Most patients received induction therapy, which was based on thymoglobulin or basi-
liximab in 41 (24%) and 109 (65%) cases, respectively. Maintenance immunosuppression was
based on calcineurin inhibitors, MMF, and steroids. Steroid withdrawal was undertaken in
57% of the subjects at 3 months after transplant. Donor-specific ELISPOT and PRT (±IL15)
data were available for all the patients.
Donor-specific ELISPOT and PRT
Pre-transplant donor-specific and PRT ELISPOTs were not associated with main baseline clin-
ical, immunological or demographic characteristics (data not shown). Donor-specific
Pre-transplant T-cell alloreactivity in kidney transplantation and allograft outcome
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ELISPOT was positive in 81 (48%) patients, while 71 (42%) and 81 (48%) patients had a posi-
tive PRT and a PRT+IL15 against at least one of the six B-cell lines, respectively. The number
of spots was of the same order of magnitude across d-sp ELISPOTs, PRT, and PRT+IL15 (50˚
percentile: 23, 18 and 26 IFN-γ spots/3x105 PBMCs, respectively), but d-sp ELISPOT had the
largest variability among the three assays as judged by its interquartile range (Table 1).
Median d-sp ELISPOTs were correlated, to a lower extent, with PRT and PRT+IL15
(rho = 0.18, P = 0.021 and rho = 0.19, P = 0.016, respectively, Fig 1A and 1B), while PRT and
PRT+IL15 were highly correlated with each other (rho = 0.96, P<0.001, Fig 1C). Median PRT
values were significantly lower compared to median PRT+IL15 values (P<0.001; Fig 2). There
was no statistically significant association between patients classified as d-sp ELISPOT positive
Table 1. Demographic and clinical characteristics of the study population.
Number of subjects 168
Living Donor % 35 (20.8)
Donor Age yrs 57.7 (16.0)
Recipients Age yrs 56.2 (13.4)
Males % 108 (64.3)
Caucasian Race % 159 (94.6)
Dialysis vintage months 30.6 (6.9–44.9)
Glomerular ESRD % 34 (20.2)
Vascular ESRD % 16 (9.5)
Tubulo-interstitial ESRD % 20 (11.9)
Diabetes ESRD % 20 (11.9)
ADPKD ESRD % 28.(16.7)
Others and unknown % 50 (29.8)
CIT (deceased donor) hours 19.1 (4.3)
HLA-I mm number 2.7 (2–3)
HLA-II mm number 1.0 (1–1)
Re-transplant % 22 (13.1)
cPRA>5% % 12 (7.1)
D+/R+ CMV status % 127 (75.6)
D+/R- CMV status % 10 (5.9)
D-/R+- CMV status % 24 (14.3)
D-/R- CMV status % 7 (4.2)
Thymoglobulin % 41 (24.4)
Basiliximab % 109 (64.9)
No induction % 18 (10.7)
Tacrolimus % 150 (89.3)
Cyclosporine % 18 (10.7)
Steroid withdrawal % 96 (57.1)
Median d-sp ELISPOT spots/3x105PBMC 23.0 (6–65)
Median PRT spots/3x105PBMC 18.1 (7.9–36.8)
Median IL-15 PRT spots/3x105PBMC 26.4 (10.4–45.4)
Continuous variables are reported as mean (standard deviation) or median (interquartile range), categorical variables
as number (percentage). D/R donor/recipient positive (+) or negative (-) CMV serum status; ESRD, End Stage Renal
Disease; PRT, Panel Reactive T-cell ELISPOT; d-sp ELISPOT, Donor-specific ELISPOT; cPRA, calculated Panel
Reactive Antibody; DSA, Donor-specific antibodies; eGFR, estimated GFR (CKD-EPI formula). Median PRT and
median PRT+IL15, median number of spots against the six B-cell lines.
https://doi.org/10.1371/journal.pone.0200696.t001
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and patients classified as PRT or PRT+IL15 positive (P = 0.64, and P = 0.44, respectively),
while there was a strong association between positive PRT and positive PRT+IL15 patients
(kappa coefficient of agreement: 0.66; P<0.001). The frequencies of PRT and PRT+IL15 spots
did not differ between patients with a positive or negative d-sp ELISPOT (data not shown).
Clinical outcomes of the study cohort
During the follow-up period, nine patients returned to dialysis and six died with a functioning
graft (48-months graft survival: 90.2% [95%CI: 84.2 to 94.1]; 48-months death censored graft
survival: 94.6% [89.8 to 97.1]. Three- and 48-month estimated eGFR were 51.1 and 45.6mL/
min/1.73m2, respectively (48-month decrease in eGFR: -5.4mL/min/1.73m2 [95%CI: -7.9 to
Fig 1. Correlation between d-sp ELISPOT (as number of spots) and median (i.e., median number of spots against the six B cell
lines) PRT (A) and PRT+IL-15 (B) (rho = 0.18, P = 0.021 and rho = 0.19, P = 0.016, respectively). Correlation between median PRT
and median PRT IL-15 (rho = 0.96, P<0.001) (C).
https://doi.org/10.1371/journal.pone.0200696.g001
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-3.0; P<0.001]. At 48 months after transplant, median proteinuria was 16 mg/24h and no
patient had proteinuria above 0.5g/24h.
Fifty-seven (42.9%) and two (5.7%) of the deceased donor and living donor recipients
respectively, developed DGF. Fifteen patients developed BPAR (8.9% [95%CI: 5.4 to 14.3]),
including one case of antibody-mediated rejection. Among 131 patients with available Lumi-
nex SAB assessment after transplantation, de novo DSAs were detected in 17 cases (13%).
Impact of pre-transplant d-sp ELISPOT and PRT assays on main graft
outcomes
Donor-specific ELISPOT, PRT and PRT+IL15 were not associated with the main baseline clin-
ical and epidemiological characteristics including number of previous transplants, type of
Fig 2. Median PRT and median PRT+IL5 (as number of spots) for each of the 168 patients.Dotted lines connect
data belonging to the same patients. The number of spots was larger with median PRT+IL15 compared to median PRT
(P<0.001 byWilcoxon matched-pairs signed-ranks test).
https://doi.org/10.1371/journal.pone.0200696.g002
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ESRD, pre-transplant sensitization, donor and recipient age and gender, ethnicity, type of
transplant or the number of HLA mismatches (Table 2).
Unexpectedly, patients who underwent steroid withdrawal had significantly lower pre-
transplant d-sp ELISPOTs compared to patients maintained on steroids (Table 2). There was
no association between pre-transplant d-sp ELISPOT, PRT or PRT+IL15 and DGF (data not
shown).
Donor-specific ELISPOT positivity was associated with a significantly higher risk of BPAR
(12/81[15%] vs. 3/87 [3%] for d-sp ELISPOT positive vs. negative, P = 0.013 respectively;
adjusted Odds Ratio, aOR: 4.20 [95%CI: 1.06 to 21.73; P = 0.041], Table 3). A positive pre-
transplant d-sp ELISPOT predicted BPAR with a negative and positive predictive value of 96%
(95%CI: 94 to 99%), and 15% (95%CI: 9 to 20%), respectively. Conversely, there was no
Table 2. Association between recipients’ pre-transplant characteristics and pre-transplant number of spots of each assay.








Difference in median PRT+IL15 number of spots/
3x105PBMC
(95%CI; P value)
Age60yrs vs <60yrs +2 (-13 to +17; P = 0.79) +2 (-5 to +10; P = 0.55) +2 (-7 to +11; P = 0.69)
Male vs female +2 (-15 to +18; P = 0.84) +1 (-7 to +10; P = 0.75) +1 (-9 to +11; P = 0.84)
Dialysis vintage5yrs vs<5yrs -11 (-34 to +13; P = 0.37) +1 (-12 to +14; P = 0.92) +2 (-13 to +18; P = 0.77)
Glomerulonephritis vs
other primary renal diseases
+8 (-11 to +27; P = 0.41) +5 (-6 to +16; P = 0.36) +6 (-7 to +19; P = 0.37)
Living vs deceased donor -5 (-22 to +13; P = 0.60) +2 (-7 to +11; P = 0.61) +6 (-6 to +18; P = 0.34)
Re-transplantation vs first
transplant
-8 (-34 to +18; P = 0.55) +1 (-14 to +16; P = 0.88) -3 (-18 to +11; P = 0.64)
cPRA> 5% per<5% -1 (-18 to +16; P = 0.89) -1 (-18 to +16; P = 0.89) -7 (-20 to +7; P = 0.34)
Thymoglobulin -14 (-29 to +1; P = 0.073) -2 (-11 to +8; P = 0.75) -2 (-12 to +8; P = 0.69)
Cyclosporine vs tacrolimus -13 (-33 to +8; P = 0.22) +3 (-11 to +16; P = 0.72) +4 (-11 to +20; P = 0.56)
Steroid withdrawal -26 (-41 to -11; P = 0.001) +2 (-6 to +10; P = 0.62) +6 (-3 to +14; P = 0.21)
Difference (95 percent confidence interval and P vale) of the number of spots of each pre-transplant assay between dichotomous categories defined by pre-transplant
recipients’ characteristics. 95%CI, 95 percent confidence interval; cPRA, calculated Panel-Rective Antibody. Median PRT and median PRT+IL15, median number of
spots against the six B-cell lines.
https://doi.org/10.1371/journal.pone.0200696.t002
Table 3. Crude and adjusted odds ratio of BPAR associated with d-sp ELISPOT.
Crude Analysis
OR (95% CI; P value)
Adjusted Analysis, Model 1
OR (95% CI; P value)
Adjusted Analysis, Model 2
OR (95% CI; P value)
Positive vs negative d-sp ELISPOT
Whole population 4.87 (1.48–21.99; P = 0.008) 3.70 (1.02–17.84; P = 0.046) 4.20 (1.06–21.73; P = 0.041)
Not receiving Thymoglobulin 6.56 (1.69–43.36; P = 0.005) 5.32 (1.25–37.01; P = 0.022) 7.87 (1.52–68.88; P = 0.012)
Number of d-sp ELISPOTs
Whole population 1.91 (1.25–2.99; P = 0.004) 1.75 (1.08–2.84; P = 0.024) 1.79 (1.02–3.10; P = 0.042)
Not receiving Thymoglobulin 1.95 (1.24–3.17; P = 0.004) 1.81 (1.09–3.06; P = 0.022) 1.89 (1.07–3.37; P = 0.029)
OR, Odds, Ratio; 95%CI, 95 percent Confidence Interval; BPAR, Biopsy-prove acute rejection; d-sp ELISPOT, donor-specific ELISPOT
The Odds Ratio associated to the number of d-sp ELISPOT is expressed per one standard deviation unit increase (i.e. 50 spots/3x105 PBMC)
Model 1, adjusted for recipient and donor age, Thymoglobulin induction (whole population only), and prednisone withdrawal
Model 2, adjusted for recipient and donor age, living (vs deceased) donor, cold ischemia time, Thymoglobulin induction (whole population only), re-transplantation,
pre-transplant HLA antibodies, HLA A/B AND HLA DR mismatch, glomerulonephritis as primary renal disease, dialysis vintage, and prednisone withdrawal.
https://doi.org/10.1371/journal.pone.0200696.t003
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association between positive PRT or PRT+IL15 and BPAR (BPAR risk in positive vs negative
patients: 6/71 [8%] vs 9/97 [9%], P = 0.54; and 6/81 [7%] vs 9/87 [10%], P = 0.59 for PRT and
PRT+IL15, respectively). When expressed per one standard deviation unit increase in the
number of spots, the aOR of BPAR was 1.79 (95%CI: 1.02 to 3.10: P = 0.042) for d-sp ELI-
SPOT, and 1.06 (0.50 to 1.95; P = 0.87) and 0.95 (0.42 to 1.82; P = 0.88) for median PRT and
median PRT+IL15, respectively (Table 3). Fig 3 shows the adjusted predicted risk of BPAR
(i.e. proportion of patients developing BPAR) according to the number of spots of d-sp ELI-
SPOT, median PRT, and median PRT+IL15, with superimposed the histograms of the actual
data distribution of the assay test results in the study population. Increased d-sp ELISPOT spot
frequencies were associated with four-time increased risk of BPAR (from zero to 150 spots
BPAR risk increased from approximately 5 to 20%), while increased median PRT and median
PRT+IL15 spots were not associated with increased BPAR risk.
The association between d-sp ELISPOT and BPAR became stronger after excluding the 41
patients who received thymoglobulin induction. In patients with positive d-sp ELISPOT not
induced with thymoglobulin, the incidence of BPAR was 12/66 (18%) vs 2/61 (3%) in patients
with negative d-sp ELISPOT (P = 0.009; aOR 7.97 [1.52 to 68.88; P = 0.012], Table 3). When
expressed per one standard deviation unit increase in the number of spots, the aOR of BPAR
increased to 1.89 (1.07–3.37; P = 0.029) for d-sp ELISPOT (Table 3), whereas the aOR
remained unchanged for median PRT and for median PRT+IL15 (aOR 1.12 [0.51–2.23;
P = 0.75], and 1.02 [0.44–2.06; P = 0.96], respectively).
There was no association between pre-transplant d-sp ELISPOT, PRT, or PRT+IL15 and de
novo DSA in the subset of 131 patients evaluated (de novo DSA risk in positive vs negative
patients: 6/70 [8.6%] vs 11/61 [18%], P = 0.11; 5/58 [8.6%] vs 12/73 [16.4%], P = 0.19; 7/66
[10.6%] vs 10/65 [15.4%], P = 0.42 for donor-reactive d-sp ELISPOT, PRT, or PRT+IL15,
respectively). Similarly, the analysis based on spots considered as a continuous variable yielded
non-significant findings (data not shown).
Fig 3. Risk of BPAR (i.e. proportion of patients developing BPAR) according to the number of IFN-γ spots for d-sp ELISPOT (A), median
PRT (B), and median PRT+IL15 (C). The solid line represents the risk of BPAR, the dashed lines represent the upper and lower 95% confidence
intervals. The risk of BPAR significantly increased with the number of spots of d-sp ELISPOT (P = 0.042), whereas it did not increase with the
number of spots of Median PRT andMedian PRT+IL15 (P = 0.87 and P = 0.88, respectively). The superimposed histograms report the frequency
distribution of the data values in the study population. The spread of the data values was larger with d-sp ELISPOT compared to Median PRT and
Median PRT+IL15. Outside the range of the actual data distribution the risk of BPAR is not reported because it would otherwise represent an
inaccurate extrapolation of the BPAR risk estimates. The plotted risk of BPAR is adjusted for recipient and donor age, living (vs deceased) donor,
cold ischemia time, Thymoglobulin induction, re-transplantation, pre-transplant HLA antibodies, HLA A/B ANDHLADRmismatch,
glomerulonephritis as primary renal disease, dialysis vintage, and prednisone withdrawal (i.e., Model 2 in Table 3). Every covariate was set to the
mean value in the study population, the indicator variate prednisone withdrawal was set to zero (i.e., no withdrawal).
https://doi.org/10.1371/journal.pone.0200696.g003
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Graft function progression and survival
After adjusting for 3-month eGFR and for baseline clinical and demographic characteristics,
median PRT and median PRT+IL15, but not d-sp ELISPOT, were significantly associated with
a sharper decline of 3-48months eGFR (Fig 4). The eGFR decline increased by -3.4mL/min/
1.73m2 (95%CI: -5.8 to -1.1; P = 0.005) and by -2.8 mL/min/1.73m2 (-5.2 to -0.3; P = 0.037) per
one standard deviation unit increase in the number of spots for median PRT and for median
PRT+IL15, respectively (Fig 4). However, positive PRT and PRT+IL15 were not significantly
correlated with 48-month eGFR decline (difference in 48 months eGFR decline between posi-
tive and negative patients: -3.9 mL/min/1.73m2 [-8.5 to +0.7; P = 0.096] and -2.3 [-7.0 to +2.3;
P = 0.32] for PRT and PRT+IL15, respectively) (Fig 4). There was no relationship between any
of the assays studied and 24h-proteinuria at 48 months after transplant (data not shown).
Being positive or negative for both the d-sp ELISPOT and the PRT (- or + IL15) assay did
not provide any prognostic advantage in predicting BPAR or eGFR change beyond every sin-
gle assay used alone (data not shown). Crude and adjusted analyses showed no significant
association between and any of the assays studied and uncensored or death-censored graft fail-
ure (data not shown).
Fig 4. Fitted means of 48-months eGFR decline frommultiple regression models for repeated measures (see text) in patients with
positive and negative d-sp ELISPOT (A), positive and negative PRT (B), positive and negative PRT+IL15 (C), and in hypothetical
patients having number of IFN-γ spots equal to the 0˚, 80˚, 90˚, and 95˚ centile of the study population for d-sp ELISPOT (D), for
median PRT (E), and for median PRT+IL15 (F). The 48-months eGFR decline did not differ significantly when comparing positive vs
negative assays, but it did differ when examining the relation with the numerical variable number-of-spots of median PRT (E) and of
median PRT+IL15 (F). According to multiple regression models, the 48-months eGFR declined by -3.4mL/min/1.73m2 (95%CI: -5.8 to
-1.1; P = 0.005) and by -2.8 mL/min/1.73m2 (-5.2 to -0.3; P = 0.037) per one standard deviation unit increase in the number of IFN-γ
spots of median PRT and median PRT+IL15, respectively. PanelsD, E, and F report the fitted 48-months eGFR decline of hypothetical
patients having number of IFN-γ spots equal to the 0˚, 80˚, 90˚, and 95˚ centile of the study population to provide a visual appraisal of the
fitted relation mentioned above between the number of IFN-γ spots and eGFR decline. Dots represent predicted means from the fitted
multiple regression models for repeated measures, vertical bars represent 95% confidence intervals. Regression models were adjusted for
3-month eGFR, recipient and donor age, living (vs deceased) donor, cold ischemia time, Thymoglobulin induction, re-transplantation,
pre-transplant HLA antibodies, HLA A/B ANDHLADRmismatch, glomerulonephritis as primary renal disease, dialysis vintage, and
prednisone withdrawal.
https://doi.org/10.1371/journal.pone.0200696.g004
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Discussion
Our large study of deceased and living kidney transplant recipients shows that positive d-sp
ELISPOT, but not PRT, identifies patients at increased risk of BPAR after transplantation,
whereas patients with high pre-transplant PRT display significant graft function loss over a
4-year follow-up period. Addition of IL15 did not increase the predictive power of the PRT
assay.
Previous studies testing the predictive power value of d-sp ELISPOT or PRT in kidney
transplant recipients prior to transplantation largely included small cohorts, have reported a
disparity of results and did not formally compare the two assays, while our data from a large
series of transplanted individuals allowed to assess the potential complementary characteristics
of both assays.
Recent works have shown a strong association between positive pre-transplant d-sp ELI-
SPOT and increased risk of BPAR after transplantation, particularly TCMR, and especially, in
patients not receiving T-cell depleting induction therapies [8,14,18]. Faddoul G and colleagues
[33] reported a close association between d-sp alloreactivity evaluated with d-sp ELISPOT and
an increased risk of BPAR and worse graft function at 2 years in positive patients. Our current
findings confirm and expand previous evidence in a larger cohort of patients, where the rela-
tionship between pre-transplant d-sp ELISPOT and a higher risk of BPAR was mainly driven
by patients not induced with Thymoglobulin. Additionally, in our group of patients, high PRT
responses also associated with worse allograft function progression. Altogether suggesting that
preformed T cell alloreactivity main negatively impact post-transplant graft outcome.
Despite the statistically significant association between pre-transplant d-sp ELISPOT and
higher risk of BPAR, only 15% of patients with positive test developed the event. On the other
hand, amongst subjects with negative assay, virtually no one developed BPAR (only 3%) thus,
highlighting the high negative predictive value of the assay enabling an accurate capacity to
identify those patients at low immunological risk that could eventually benefit of receiving less
immunosuppression.
We did not find any association between a positive pre-transplant d-sp ELISPOT and
worse allograft function progression after transplantation. Nonetheless, while some studies
have showed such correlation, particularly among patients not receiving T-cell induction ther-
apy [14,20], some other groups have not been able to find such association before transplanta-
tion [8,13,16,34,35] but have conversely found a consistent relationship between worse kidney
allograft function progression and the d-sp ELISPOT when assessed after transplantation sug-
gesting a much close illustration of the on-going anti-donor T-cell alloimmune response of
transplant patients.
To the best of our knowledge, the current study is the largest work testing the association
between pre-transplant PRT and graft outcomes. In contrast with previous few smaller studies
[22], we did not detect a relationship between PRT and BPAR. A previous study identified an
inverse nonsignificant trend between pre-transplant PRT and eGFR. The large sample size of
our cohort and long-term follow-up, allowed us to find a significant association between the
frequency of pre-transplant PRT and PRT+IL15 and eGFR decline at 4 years. This association
suggests that patients with a broad pre-transplant alloreactive T-cell repertoire, expressed by
means of high PRT, may be at increased risk of the formation of crossreactive T and B cells
with allo- and auto-reactive specificities that may lead to progressive but smoldering subclini-
cal allograft damage. Unfortunately, lack of surveillance graft biopsies or measurement of cir-
culating auto- or allo-antibodies in a significant fraction of patients prevented us from
confirming this hypothesis.
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Adding IL15 to the PRT did not increase the predictive power of the assay, indicating that the
circulating CD8+CD28- Tmemmeasured before engraftment do not play a major role in the path-
ogenesis of subsequent allograft injury, at least in patients on calcineurin inhibitor-based immu-
nosuppression. This is consistent with our preliminary data suggesting that the number of these
cells before transplant predicted acute rejection only in kidney transplant recipients receiving
costimulation blockade-based immunosuppression with CTLA4Ig (Cravedi P, Gandolfini I,
Donadei C, et al. Pre-Transplant Panel Reactive T Cells (PRT) with IL-15 as a Risk-Stratifier of
Acute Rejection in Kidney Transplant Patients on Belatacept Therapy. American Transplant Con-
gress. Chicago, May 2017. Abstract). Further studies, however, are needed to define the utility of
PRT+IL15 in predicting graft outcomes in kidney transplant recipients.
We found no relationship between any of the pre-transplant assays and the development of
DSA. While missing data on DSA development may have prevented us from detecting such
relationship, these data are in agreement with our 2017 recent study [8] showing that only
post-transplant, but not pre-transplant d-sp ELISPOT can inform on the risk of developing
DSA. This data together with the absence of association with graft function progression over
time highly suggest that monitoring anti-donor T-cell alloreactivity after kidney transplanta-
tion may be particularly useful to gain more insight about the alloimmune state of transplant
patients after having received the initial high burden of induction immuosuppression and
thus, more accurately indicate how such immune state may progressively impact on long-term
allograft outcomes.
We acknowledge that our study has some limitations. Firstly, it was a single-center, retro-
spective study. However, main aim of this study was to perform the first large comparison
between the two main assays to measure T-cell alloreactivity that could be implemented in
clinical practice in the short term. In addition, the use of only six B-cell lines might have
restricted the broad allogenic repertoire of the transplant recipients evaluated in this study and
therefore, might have prevented a more granular differentiation between patients, as it occurs
with the PRA assays. However, the findings of the current study set the basis for subsequent
investigations to test the predictive power of PRT based on a more extensive panel of B-cell
lines.
Due to the limited amount of PBMC available, we could not perform d-sp ELISPOT in the
presence of IL15 and thus, future studies will be important in assessing are warranted to test
the utility of such assay in predicting graft outcomes.
Conclusions
Our findings confirm and further expand previous evidence showing that measuring alloreac-
tive Tmem before transplantation by d-sp ELISPOT or PRT allows to predict relevant
immune-mediated transplant outcomes that would not be forecasted by current standard clin-
ical and immunological evaluations. Present findings do not support the use of IL15 in the
PRT assay, but further studies are needed to define its utility, especially in patients not receiv-
ing calcineurin inhibitor immunosuppression. Our data set the basis of prospective studies for-
mally testing the hypothesis that tailoring immunosuppression based on the joint use of d-sp
ELISPOT and PRT improves patients’ outcomes.
Supporting information
S1 Fig. Analysis of the best choice among different combinations of PBMCs and B cells in
order to reproduce the results from the standard PRT assay, which is traditionally based
on a 300.000 PBMCs to 100.000 B cells ratio per well. Each plot represents the linear correla-
tion between a PBMCs to B cells ratio combination (x-axis) selected in order to minimize the
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number of cell used, and the standard 300.000 PBMCs/100.000 B cells combination (y axis).
The 100.000 PBMCs to 60.000 B cells ratio (left-lower-most panel) showed an excellent corre-
lation with the standard 300.000 PBMCs to 100.000 B cells ratio (R2 = 0.94) and was therefore
used for the PRT assays in the current study. Each dot represents the average of two wells.
(DOCX)
S2 Fig. Percentage of expression of HLA A, B and DR alleles and coverage to donor HLA
repertoires provided by B cell lines. Expression of B cell panel HLA alleles represented
61.95%, 59.27% and 78.86% of expression over all HLA A, HLA B and HLA DR alleles
expressed, respectively. Red bars represent HLA alelles that were in common with the B cell
lines.
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S1 Table. HLA typing of the six B cell lines used as stimulators in the PRT assay.
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